Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007341
Chunk: 115

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 115
---
center'>EXPERTS</div>

The financial statements as of December
31, 2024, and for the year then ended, incorporated by reference into this prospectus and in the registration statement have been so incorporated
in reliance on a report PKF Littlejohn LLP, an independent registered accounting firm, given on authority of said firm as experts in auditing
and accounting. The report on the financial statements for the year ended December 31, 2024 contains an explanatory paragraph regarding
our ability to continue as a going concern.

PKF Littlejohn LLP, London, United Kingdom,
is a member of the Institute of Chartered Accountants in England and Wales.

The financial statements of
Biodexa Pharmaceuticals PLC as of December 31, 2023, and for each of the three years in the period then ended, incorporated by reference
in this prospectus and in the registration statement have been so incorporated in reliance on a report of Forvis Mazars LLP (then-named
Mazars LLP), an independent registered public accounting firm, given on authority of said firm as experts in auditing and accounting.
The report on the financial statements for the year ended December 31, 2023, contains an explanatory paragraph in Note 2 regarding our ability to continue as a going concern.

Forvis Mazars LLP, London, United Kingdom,
is a member of the Institute of Chartered Accountants in England and Wales.

<div align='center'>ENFORCEMENT OF CIVIL LIABILITIES</div>

We are incorporated under the laws of England
and Wales. All of our directors and officers of are residents of jurisdictions outside the United States. Our corporate headquarters is
located in the United Kingdom and all or a substantial portion of our assets, and all or a substantial portion of the assets of our directors
and officers, are located outside of the United States. As a result, it may be difficult for you to serve legal process on us or our directors
or have any of them appear in a U.S. court.

We have appointed
Donald J. Puglisi of Puglisi & Associates as our authorized agent upon whom process may be served in any action instituted in any
U.S. federal or state court having subject matter jurisdiction arising out of or based upon the securities offered by this prospectus.

We understand that
in England it may not be possible to bring proceedings or enforce a judgment of a U.S. court in respect of civil liabilities based solely
on the federal securities laws of the